Overview

Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072

Status:
Completed
Trial end date:
2019-01-24
Target enrollment:
0
Participant gender:
Male
Summary
The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2071 and AD-2072 in healthy male volunteers.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Addpharma Inc.
Criteria
Inclusion Criteria:

- Healthy male between 19 and 50 years of age at the time of screening

- Weight between 50 kg and 90 kg and body mass index (BMI) between 18.0 kg/m2 and 27.0
kg/m2

Exclusion Criteria:

- Clinically significant disease or history of clinically significant disease such as
liver, kidney, nervous system, respiratory, endocrine*hematologic, cardiovascular,
urinary, psychiatric

- Gastrointestinal problem or history of gastrointestinal problem and history of
gastrointestinal surgery

- HDL values less than 35 mg/dL

- AST, ALT values over than 1.5 times of ULN at screening

- A person who has a history of drug abuse or who has positive result for an abuse drug
in a urine screening test